Eisai’s CEO Naito Participated in Online Event “Deliver 18 new treatments by 2028 – The future of partnerships and role of Japan”

  • Share
  • Tweet
  • Share
  • Tweet

July 20, 2021

Eisai Co., Ltd. (Eisai) is jointly developing new drugs for neglected tropical diseases with the Drugs for Neglected Diseases initiative (DNDi), an international non-profit organization. Eisai’s CEO Haruo Naito participated in DNDi’s online event “Deliver 18 new treatments by 2028 – The future of partnerships and role of Japan” which was held on June 30, 2021. Currently, Eisai and DNDi are jointly developing Eisai’s in-house discovered antifungal agent fosravuconazole (E1224) as a treatment for mycetoma, a neglected tropical disease. Furthermore, Eisai and DNDi have established a long-term partnership and are collaborating on other neglected tropical diseases such as leishmaniasis.

Participants of the event

DNDi has announced a new strategic plan aiming to deliver 18 new treatments by 2028 in collaboration with partners. A panel of leaders and experts of industry, government and academia including Eisai’s Naito discussed what Japan can do for neglected patients and what is needed for future R&D partnerships. Please visit here to watch the event. 

Event held on June 30, 2021

Eisai will continue to work on developing new drugs for neglected tropical diseases such as mycetoma and leishmaniasis with its global partners, including DNDi.

  

  

Sustainability

Related Links